Brief: First Report Of Positive Dose Escalation Data Supports Best-In-Class Profile For Investigational Exarafenib As A Single Agent And In Combination With Binimetinib In Braf-Altered Cancers And Nras Mutant Melanoma

Kinnate Biopharma

17/04/2023 19:39

April 17 (Reuters) - Kinnate Biopharma Inc  KNTE.O :
    * FIRST REPORT OF POSITIVE DOSE ESCALATION DATA SUPPORTS
BEST-IN-CLASS PROFILE FOR INVESTIGATIONAL EXARAFENIB AS A SINGLE
AGENT AND IN COMBINATION WITH BINIMETINIB IN BRAF-ALTERED
CANCERS AND NRAS MUTANT MELANOMA
    * KINNATE BIOPHARMA INC: EXARAFENIB WAS WELL-TOLERATED AT
SUBSTANTIAL MONOTHERAPY EXPOSURES
    * KINNATE BIOPHARMA: BREADTH OF RESPONSES OBSERVED ACROSS
TUMOR
TYPES, BRAF OR NRAS ALTERATIONS WITH 8 PARTIAL RESPONSES IN
MONOTHERAPY & COMBO ARMS
    * KINNATE BIOPHARMA INC: 3% (N=2/60) OF PATIENTS
DISCONTINUED
THERAPY DUE TO TREATMENT-RELATED ADVERSE EVENTS IN EXARAFENIB
MONOTHERAPY EXPOSURES
    * KINNATE BIOPHARMA INC: MONOTHERAPY DOSE EXPANSION ONGOING
AT 300
MG BID
    * KINNATE BIOPHARMA INC: DOSE SELECTION EXPECTED IN SECOND
HALF OF
2023 FOR EXARAFENIB COMBINATION ARM IN NRAS MUTANT MELANOMA

Further company coverage:  KNTE.O 

 ((Reuters.Briefs@thomsonreuters.com;))